vs
Side-by-side financial comparison of DNA X, Inc. (SONM) and TriSalus Life Sciences, Inc. (TLSI). Click either name above to swap in a different company.
DNA X, Inc. is the larger business by last-quarter revenue ($16.2M vs $13.2M, roughly 1.2× TriSalus Life Sciences, Inc.). DNA X, Inc. runs the higher net margin — -29.3% vs -73.9%, a 44.5% gap on every dollar of revenue. On growth, TriSalus Life Sciences, Inc. posted the faster year-over-year revenue change (59.8% vs 7.9%). Over the past eight quarters, TriSalus Life Sciences, Inc.'s revenue compounded faster (43.0% CAGR vs 9.9%).
TriSalus Life Sciences, Inc. is a clinical-stage biotechnology company focused on advancing immuno-oncology and interventional oncology solutions. It develops proprietary targeted drug delivery technologies designed to improve treatment efficacy for patients with liver, pancreatic and other hard-to-treat solid tumors, primarily operating in North American markets via partnerships with clinical care and research institutions.
SONM vs TLSI — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.2M | $13.2M |
| Net Profit | $-4.8M | $-9.8M |
| Gross Margin | 11.2% | 86.7% |
| Operating Margin | -24.5% | -24.8% |
| Net Margin | -29.3% | -73.9% |
| Revenue YoY | 7.9% | 59.8% |
| Net Profit YoY | -89.2% | 3.5% |
| EPS (diluted) | $-4.83 | $-0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $13.2M | ||
| Q3 25 | $16.2M | $11.6M | ||
| Q2 25 | $11.2M | $11.2M | ||
| Q1 25 | $16.7M | $9.2M | ||
| Q4 24 | $15.3M | $8.3M | ||
| Q3 24 | $15.0M | $7.3M | ||
| Q2 24 | $11.5M | $7.4M | ||
| Q1 24 | $9.1M | $6.5M |
| Q4 25 | — | $-9.8M | ||
| Q3 25 | $-4.8M | $-10.8M | ||
| Q2 25 | $-7.5M | $-8.3M | ||
| Q1 25 | $458.0K | $-10.4M | ||
| Q4 24 | $-21.6M | $-10.1M | ||
| Q3 24 | $-2.5M | $-2.4M | ||
| Q2 24 | $-6.6M | $-4.3M | ||
| Q1 24 | $-2.9M | $-13.2M |
| Q4 25 | — | 86.7% | ||
| Q3 25 | 11.2% | 83.5% | ||
| Q2 25 | 7.6% | 83.9% | ||
| Q1 25 | 50.0% | 83.7% | ||
| Q4 24 | -1.2% | 85.3% | ||
| Q3 24 | 28.2% | 86.3% | ||
| Q2 24 | 25.8% | 87.6% | ||
| Q1 24 | 31.8% | 85.0% |
| Q4 25 | — | -24.8% | ||
| Q3 25 | -24.5% | -77.9% | ||
| Q2 25 | -60.2% | -65.4% | ||
| Q1 25 | 3.9% | -79.9% | ||
| Q4 24 | 55.3% | -91.8% | ||
| Q3 24 | -15.8% | -118.9% | ||
| Q2 24 | -56.2% | -111.0% | ||
| Q1 24 | -29.5% | -180.8% |
| Q4 25 | — | -73.9% | ||
| Q3 25 | -29.3% | -93.5% | ||
| Q2 25 | -66.8% | -73.9% | ||
| Q1 25 | 2.7% | -113.2% | ||
| Q4 24 | -141.6% | -122.4% | ||
| Q3 24 | -16.7% | -32.6% | ||
| Q2 24 | -57.5% | -58.8% | ||
| Q1 24 | -31.9% | -204.5% |
| Q4 25 | — | $-0.22 | ||
| Q3 25 | $-4.83 | $-0.96 | ||
| Q2 25 | $-0.79 | $-0.27 | ||
| Q1 25 | $0.08 | $-0.39 | ||
| Q4 24 | $-116.99 | $-0.38 | ||
| Q3 24 | $-9.32 | $-0.12 | ||
| Q2 24 | $-1.41 | $-0.21 | ||
| Q1 24 | $-0.65 | $-0.60 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.1M | $20.4M |
| Total DebtLower is stronger | $5.1M | — |
| Stockholders' EquityBook value | $-701.0K | $-33.9M |
| Total Assets | $40.2M | $35.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $20.4M | ||
| Q3 25 | $2.1M | $22.7M | ||
| Q2 25 | $2.0M | $26.5M | ||
| Q1 25 | $2.1M | $13.0M | ||
| Q4 24 | $5.3M | $8.5M | ||
| Q3 24 | $9.1M | $11.3M | ||
| Q2 24 | $9.6M | $16.5M | ||
| Q1 24 | $9.3M | $4.0M |
| Q4 25 | — | — | ||
| Q3 25 | $5.1M | — | ||
| Q2 25 | $2.9M | — | ||
| Q1 25 | $2.8M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $-33.9M | ||
| Q3 25 | $-701.0K | $-26.7M | ||
| Q2 25 | $-1.3M | $-19.4M | ||
| Q1 25 | $-1.1M | $-34.4M | ||
| Q4 24 | $-5.7M | $-25.9M | ||
| Q3 24 | $15.3M | $-20.4M | ||
| Q2 24 | $17.5M | $-25.3M | ||
| Q1 24 | $19.8M | $-36.0M |
| Q4 25 | — | $35.3M | ||
| Q3 25 | $40.2M | $36.5M | ||
| Q2 25 | $36.1M | $41.3M | ||
| Q1 25 | $36.0M | $28.6M | ||
| Q4 24 | $39.7M | $24.0M | ||
| Q3 24 | $49.1M | $27.5M | ||
| Q2 24 | $45.9M | $32.4M | ||
| Q1 24 | $42.4M | $17.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-7.0M | $-2.5M |
| Free Cash FlowOCF − Capex | — | $-2.5M |
| FCF MarginFCF / Revenue | — | -19.1% |
| Capex IntensityCapex / Revenue | — | 0.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-19.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-2.5M | ||
| Q3 25 | $-7.0M | $-3.7M | ||
| Q2 25 | $-4.9M | $-7.3M | ||
| Q1 25 | $-9.6M | $-4.5M | ||
| Q4 24 | $-4.5M | $-5.7M | ||
| Q3 24 | $-417.0K | $-10.8M | ||
| Q2 24 | $-3.4M | $-13.4M | ||
| Q1 24 | $-168.0K | $-10.9M |
| Q4 25 | — | $-2.5M | ||
| Q3 25 | — | $-3.9M | ||
| Q2 25 | — | $-7.4M | ||
| Q1 25 | — | $-5.3M | ||
| Q4 24 | $-4.5M | $-5.8M | ||
| Q3 24 | $-554.0K | $-11.0M | ||
| Q2 24 | $-3.4M | $-13.5M | ||
| Q1 24 | $-198.0K | $-10.9M |
| Q4 25 | — | -19.1% | ||
| Q3 25 | — | -33.9% | ||
| Q2 25 | — | -66.1% | ||
| Q1 25 | — | -57.3% | ||
| Q4 24 | -29.6% | -69.7% | ||
| Q3 24 | -3.7% | -149.9% | ||
| Q2 24 | -29.8% | -183.1% | ||
| Q1 24 | -2.2% | -169.3% |
| Q4 25 | — | 0.3% | ||
| Q3 25 | — | 1.9% | ||
| Q2 25 | — | 0.8% | ||
| Q1 25 | — | 8.2% | ||
| Q4 24 | 0.1% | 0.6% | ||
| Q3 24 | 0.9% | 2.3% | ||
| Q2 24 | 0.3% | 0.8% | ||
| Q1 24 | 0.3% | 1.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -20.97× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
